Drug profile · INN
odronextamab
ORDSPONO
odronextamab (ORDSPONO) is a b-lymphocyte antigen cd20 binding agent. Associated with Regeneron UK Limited.
EMA: approved Nervous system (NOT) Not yet assigned
Patents linked 0
Pipeline programs 12
News articles 0
Drug details — odronextamab
- Class
- Nervous system (NOT)
- Route
- —
- Patents
- 0
- Programs
- 12
- Data quality
- 0.89
Quick answer
odronextamab (ORDSPONO) is a b-lymphocyte antigen cd20 binding agent. Associated with Regeneron UK Limited.
Key facts
INN odronextamab
Brand ORDSPONO
Mechanism B-lymphocyte antigen CD20 binding agent
Target B-lymphocyte antigen CD20
Therapeutic class Nervous system (NOT)
ATC code Not yet assigned
Originator Regeneron UK Limited
Mechanism of action
B-lymphocyte antigen CD20 binding agent
Primary target: B-lymphocyte antigen CD20
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is odronextamab?
odronextamab (ORDSPONO) is a b-lymphocyte antigen cd20 binding agent. Associated with Regeneron UK Limited.
What is the brand name for odronextamab?
ORDSPONO is a marketed brand name for odronextamab. Check FDA Drugs@FDA for the current US label holder and prescribing information.